VALEO PHARMA’S HESPERCO(TM) CAPSULES AT THE CORE OF MONTREAL HEART INSTITUTE’S HESPERIDIN – RICH TV LIVE – fEBRUARY 21, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.
Hi how’s everybody doing today i’m your host rich from rich tv live with our very special guest the ceo of valio pharma steve savieck with some huge news today some huge breaking news today how you doing today steve very good rich nice to be back on your show love having you on the show and i want to talk about the big breaking news you’ve announced this
Morning that the montreal heart institute will be conducting a trial on covin 19 with your hesperco capsules can you tell us what the medicinal medical ingredient hesperidine contained in the capsule does exactly and where it comes from okay well uh the asparadine is uh derived from the crust of citrus fruit it’s processed into a specific formulation of
Pure asparagus asparty it has over 20 years shown some very interesting properties in terms of viral defense the specific on corona viruses which are around us and have been for the last 20 years various variants uh it does three things or is thought to do three things one is reduce infection second is to reduce uh replication and third is to support your
Immune system against the inflammatory response that comes from your body so it has really three modes of action um and uh it’s again shown in over 150 scientific journals a lot of research done on this paradigm over the last 20 years since the original outbreak of uh serious car cyrus goal won back in 2002. fantastic and how did you get the montreal heart
Institute to be interested in conducting a clinical trial on hesperidine we partnered up we value farmer last march with a company that we’ve known for quite some time called ingenue pharma and ingenue farm is a small biotech company in montreal they did a lot of the initial ground work on finding uh hesperidine and looking at all the scientific literature
They put together quite a uh i guess an in-depth scientific proposal that the montreal heart institute uh reviewed and accepted as being very interesting and warranting further research valio is part of the of the equation was putting together the formulations manufacturing the product helping with the health canada submission and ultimately commercializing
The product as we’re doing now the scientists at your development partner agnew pharma which you just mentioned have done extensive and exhaustive scientific research and it seems like hesperidine has all these great anti-inflammatory and antioxidant properties with a great safety profile it almost looks too good to be true why haven’t we seen other pharma
Companies interested in pursuing a trial on hesperidine well as the ceo of ingenue pharma is fond to say um you couldn’t manufacture a product that had these properties you stumble upon one and it’s really a sort of just a uh done haphazardly in the sense that there was a lot of screening of molecules when the original sars outbreak happened in early uh 2002.
Uh this was one product that just uh drew attention because of its properties why doesn’t big pharma go after this um i would say it’s a natural product it has probably lower pricing potential than big pharma would typically want to see and those are the the main reasons this is a very inexpensive product dollar a day we call it and two capsules provide you
With a thousand milligrams which is a health canada’s recommended daily dose i think that’s great a dollar a day to maintain your health is a great preventative solution and option for canadians and americans and potentially investors and potentially patients all over the world for your company now why should people be interested in taking or continuing to
Take hesperco with the vaccines getting rolled out to more and more people well there’s a number of uh of reasons number one is certainly prior to i mean this is not a product that we recommend you take only if you feel ill although a lot of people will as you would typically take other you know ingredients when you feel the symptoms of some cold or what
Have you you could take this prior it we believe it has enough other properties that are beneficial to the body in addition to potentially preventing the the the viral load or the amount of virus from entering your body it has that property uh the second is uh you know the vaccines are are absolutely the way people should go i mean they clearly but not
Everyone’s going to be taking a vaccine and even if you take the vaccines there is this this element of you know efficacy which is seen to be in the 90-plus percent range so there still is a chance that you will get um you could get infected by the uh the virus and the second is the vaccine is not a a for life kind of vaccine it has to be taken on a regular
Basis that’s the expectation of people that the vaccine will so i i would say primarily people should take the vaccine while you’re waiting for the vaccine take a spare call but also i think take a take asparagus against other viruses that could be potentially infectious to the body so it’s really something that is has a lot of different properties uh that
Are beneficial to the body and and patients regardless of being vaccinated or not should continue uh in our view to uh to and i certainly expect to do that as well as a lot of our colleagues um continue to take a spare time so what we’re noticing now and we’re seeing it in other places all over the world is that there’s different variants of the virus so
Will hesperidine work on those variants as well the the it’s early to tell right now but uh what we believe and what ingenue believes more specifically than they’re doing a lot of the work on it is the the virus needs to enter your body and regardless of the variance the the it enters your body through the same mechanism so the expectation and through the
Same portal which is your ace2 uh receptors which are commonly in your lung so as long as there is a prevention aspect which is what experimenting one of the properties asparagus is thought to have uh it would you know the theory is again it’s theory because these virus environ variants are so new is that they’re there but they act we know they act in the
Same way that we should have the same kind of beneficial effect to to patients wow that would be incredible because from what i’m hearing a lot of the vaccines are not working with some of these new variants so if harris if if your product does then that will be a huge breakthrough for the company so that’ll be exciting to see how that rolls out now you
Mentioned that hesperico will be available in retailers when will it go on sale and which retailers can we expect to see it in it well currently it is on sale it is for sale online through our own website at sparecode.com but also through amazon.ca and amazon quite a bit of it since we launched uh late november um in terms of the traditional bricks and mortar
Retailers you could expect to see rexella shoppers drug mart these type of retailers having availability of this product in the coming weeks we’ve been in discussion with all of them marketing plans are being put together and and programs to in terms of being making the product visible to consumers are all in the works uh so i can’t give you definitive date
But i would continue to to to tell your uh you know if you want to own the product or buy it buy it today online but by all means go to your your local pharmacy and ask for it and or at least put yourself on a list that as soon as they get it you’ll be made aware and they can they can you can pick it up at these pharmacies we will be going into the u.s also
Probably early march initially again through amazon u.s retail market is much more fragmented than the canadian market a lot of different banners a lot of different stores out there so it the rollout is we’re discussing that with a potential u.s partner in terms of how that’s going to happen but uh we’ve actually manufactured u.s labor products so that’s the
Expectation that we’ll be launching the u.s shortly that’s going to be huge for valeo pharma i’m excited to see what happens with you guys when that happens typically when we see companies move into the u.s it’s just an explosion of revenue and explosion of growth and typically price appreciation as well so that’ll be exciting to see now how long and i know
You mentioned you can’t really mention exactly but just to give us an estimate how long will the study last and when can we expect to see some results well the study is uh has a total number of patients forecasted about 216. it’s got two arms so one is known as the placebo arm so they’re taking essentially a sugar capsule versus asparagine capsule so the
The research can identify the benefits of asparagine over the placebo so typical uh clinical uh practice um there’s a lot of cases as you know in quebec and therefore a lot of patients potentially to recruit from our expectation is probably 90 to 120 days the trial should be complete at which point there would be some type of information it could go longer
Than that it’s very unique it’s a it’s a distance trial so in other words patients don’t go to the montreal heart institute they enroll and all of the documentation and product is actually shipped to them at their uh home or office but for not probably more so home so this is a kind of a new way of doing some clinical trials where it’s harder to get people to
Actually you know come into a facility so we’re trying to do it at distance looking forward to the results i think it’s i think a lot of people are i’m excited about seeing what the results are going to look like and i know our community is now our community has been following value of pharma for quite some time now and it’s been a success story so far and we
Love revenue and revenue growth we love tight float stocks we love growing companies and you guys literally fit the bill now can you provide us with a revenue forecast from the sales of aspergo and what it could represent to the bottom line of value of pharma um okay we’ll we’ll i’ll just give you a bit of background so we finished our last fiscal year ending
October with approximately 8 million of revenue that we’re forecasting that to grow to about 20 to 25 million this year wow um that’s from our existing products that are continuing to grow and two uh two big revenue drivers that we foresee which is hesperico being one the other is radesca our low molecular weight heparin that we’re launching uh late spring
Early summer uh which we think will have a top line uh uh sort of peak sales of in the 30 plus million range for radessa esparco is very uh difficult to forecast i mean our forecasts are relatively low uh six to ten million uh they could be that number could be multiplied by many but we’re trying to be as conservative as we can in terms of our our investors
We think that if we do 20 to 25 this year with another probably 20 million edition year after uh we’re well you know we believe we’re well on our way to being a 60 80 million dollar revenue company in the next three four years potentially sooner uh and a lot of it is on the back as they say every desk on spherical but we have a number of other products our
Parkinson’s drug that we launched a year and a half ago is starting to to do well and uh and some of our other uh injectables that we’ve launched during the course of last year so uh people can expect to see that 20 25 million dollar range um and profitability by the end of this fiscal year wow really excited to see everything unfold and guys remember rich
Tv live is strictly for education and entertainment purposes always do your due diligence always do your research before you invest in anything that we discuss or talk about here in rich tv live if you like the video please smash the like button comment down below share the video everywhere and subscribe and feel free to contact steve yourself get in contact
With the company if you have any questions if you’re an investor and you’d like to learn more steve is very willing to communicate with shareholders and thank you guys for watching if you’re not winning you’re not watching we bring in the winners and we bring them to you first i think this is a company that’s undervalued under-appreciated underexposed when you
Look at big pharma companies you see these huge billion dollar giants this is a company that i think has a chance to one day grow to become a big pharma company but you’re getting an opportunity to literally get in in the early stages while there’s still a micro cap stock so in my opinion huge upside for value of pharma and we get an opportunity to position
Ourselves and grow with the company thank you so much for your time today steve congratulations on all your success thus far and we’ll be watching along the way yeah look forward to being back with uh updates and more news yeah and like i said if you ever have any big breaking news like this uh that you’d like to introduce to our community love to invite you
Back on our show at your convenience keep up all the great work and thank you for joining us today thank you thank you steve thank you guys for watching have yourselves a great day
Transcribed from video
VALEO PHARMA'S HESPERCO(TM) CAPSULES AT THE CORE OF MONTREAL HEART INSTITUTE'S HESPERIDIN By RICH TV LIVE
